The assessment of the effectiveness and safety of teduglutide in the treatment of children with chronic intestinal insufficiency. A systematic review

Abstract

Chronic intestinal failure is a pathogenetic component in children with short bowel syndrome. Short bowel syndrome limits the patient's capacity to socialize fully, the bad prognosis of the child's physical and spiritual development, and the patient's family's organizational and material issues. The severity of the problem is aggravated by the limited prospects for surgical treatment of patients, including transplantology, the imperfection of the legal framework for health care, particularly in terms of parenteral nutrition at home, and the supply of expensive drugs, consumables, and equipment to children with short bowel syndrome under state guarantees. Developing an equivalent of glucagon-like peptide-2 (GLP-2), a drug teduglutide representing the endogenous intestinal growth factor and intestinal adaptation, created an additional therapeutic possibility for individuals with short bowel syndrome. There are no data in Russian academic literature on the efficacy and safety of teduglutide in pediatric practice.

This study aims to conduct a systematic search and critical analysis of publications on the effectiveness and safety of using teduglutide in children with short bowel syndrome.

Publications from the PubMed, Scopus, and eLibrary databases, as well as scientific journals, were examined from 2012 to 2022. The articles were reviewed in English and Russian. Seven hundred seventy publications on using teduglutide in experimental and clinical practice were found; 94 sources matched the keywords; and eight articles were selected according to the PRISMA criteria. The risks of confounding bias were assessed using the ROBINS-I tool. Most patients received the therapeutic impact of teduglutide, and 8.4%–64.7% of patients achieved enteral autonomy. The drug's dose was 0.05 mg/kg/day. Without a therapeutic effect, the time limits for the inappropriate use of teduglutide ranged from 6 months to 1 yr. There is no causal relationship between taking teduglutide and undesirable reactions to treatment. The review of publications revealed an insufficient evidence foundation for the efficacy of teduglutide due to a lack of control groups in most studies, a small sample size, and errors in data methodology. Despite the encouraging preliminary results of individual studies, the problem of a shortage of randomized controlled tests of teduglutide remains.

Keywords

glp-2 analog / intestinal failure / parenteral nutrition / pediatrics / short bowel syndrome / systematic review / teduglutide

References

[1] Stollman NH, Neustater BR, Rogers AI. Short-bowel syndrome. Gastroenterologist. 1996;4(2):118–128.

[2] Stollman N.H., Neustater B.R., Rogers A.I. Short-bowel syndrome // Gastroenterologist. 1996. Vol. 4, No. 2. P. 118–128.

[3] Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012;5(3):159–171. DOI: 10.1177/1756283X11436318

[4] Jeppesen P.B. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome // Therap Adv Gastroenterol. 2012. Vol. 5, No. 3. P. 159–171. DOI: 10.1177/1756283X11436318

[5] Vanderhoof JA. Short bowel syndrome. Clin Perinatol. 1996;23(2):377–386. DOI: 10.1016/S0095-5108(18)30247-1

[6] Vanderhoof J.A. Short bowel syndrome // Clin Perinatol. 1996. Vol. 23, No. 2. P. 377–386. DOI: 10.1016/S0095-5108(18)30247-1

[7] Rozinov VM. Short bowel syndrome in children: results of the conference. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2021;11(2):221–225. (In Russ.) DOI: 10.17816/psaic342

[8] Сухотник И.Г. Синдром короткой кишки у детей // Российский вестник детской хирургии, анестезиологии и реаниматологии. 2017. Т. 7, № 3. C. 98–115. DOI: 10.17816/psaic342

[9] Rosete BE, Wendel D, Horslen SP. Teduglutide for pediatric short bowel syndrome patients. Expert Rev Gastroenterol Hepatol. 2021;15(7):727–733. DOI: 10.1080/17474124.2021.1913052

[10] Rosete B.E., Wendel D., Horslen S.P. Teduglutide for pediatric short bowel syndrome patients // Expert Rev Gastroenterol Hepatol. 2021. Vol. 15, No. 7. P. 727–733. DOI: 10.1080/17474124.2021.1913052

[11] Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide — analyses from a randomised, placebo-controlled study. Clin Nutr. 2013;32(5):713–721. DOI: 10.1016/j.clnu.2013.03.016

[12] Jeppesen P.B., Pertkiewicz M., Forbes A., et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide — analyses from a randomised, placebo-controlled study // Clin Nutr. 2013. Vol. 32, No. 5. P. 713–721. DOI: 10.1016/j.clnu.2013.03.016

[13] Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. J Parenter Enteral Nutr. 2014;38(S1):45S–52S. DOI: 10.1177/0148607114526241

[14] Jeppesen P.B. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome // J Parenter Enteral Nutr. 2014. Vol. 38, No. S1. P. 45S–52S. DOI: 10.1177/0148607114526241

[15] Kim ES, Keam SJ. Teduglutide: A review in short bowel syndrome. Drugs. 2017;77(3):345–352. DOI: 10.1007/s40265-017-0703-7

[16] Kim E.S., Keam S.J. Teduglutide: A review in short bowel syndrome // Drugs. 2017. Vol. 77, No. 3. P. 345–352. DOI: 10.1007/s40265-017-0703-7

[17] Certificate of state registration of the computer program RUS No. 2016615129/ 17.05.2016. Chernikov MV, Novikova AN, Mazurov NYa, et al. Universal’nyi programmnyi kompleks dlya sbora, obrabotki i upravleniya territorial’no raspredelennymi kliniko-ehpidemiologicheskimi dannymi v rezhime udalennogo dostupa. Available at: http://www1.fips.ru/Archive/EVM/2016/2016.06.20/DOC/RUNW/000/002/016/615/129/document.pdf (In Russ.)

[18] Свидетельство о государственной регистрации программы ЭВМ РФ № 2016615129/ 17.05.2016. Черников М.В., Новикова А.Н., Мазуров Н.Я., и др. Универсальный программный комплекс для сбора, обработки и управления территориально распределенными клинико-эпидемиологическими данными в режиме удаленного доступа. Доступ по: http://www1.fips.ru/Archive/EVM/2016/2016.06.20/DOC/RUNW/000/002/016/615/129/document.pdf

[19] Rozinov VM, Ampar FB, Samorokovskaya MV, Isakov MA. Organizational and clinical potential of the Federal Register of children with short bowel syndrome. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2022;12(1):73–84. (In Russ.) DOI: 10.17816/psaic1229

[20] Розинов В.М., Ампар Ф.Б., Самороковская М.В., Исаков М.А. Организационный и клинический потенциал Федерального регистра детей с синдромом короткой кишки // Российский вестник детской хирургии, анестезиологии и реаниматологии. 2022. Т. 12, № 1. С. 73–84. DOI: 10.17816/psaic1229

[21] ema.europa.eu [Internet]. NPS Pharma Holdings Limited. Revestive (teduglutide) 5 mg powder and solvent for solution for injection: EU summary of product characteristics. 2016 [cited 2017 Jan 31]. Available at: http://www.ema.europa.eu

[22] ema.europa.eu [Электронный ресурс]. NPS Pharma Holdings Limited. Revestive (teduglutide) 5 mg powder and solvent for solution for injection: EU summary of product characteristics. 2016 [дата обращения: 31.01.2017]. Доступ по: http://www.ema.europa.eu

[23] McMellen ME, Wakeman D, Longshore SW, et al. Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg. 2010;19(1):35–43. DOI: 10.1053/j.sempedsurg.2009.11.010

[24] McMellen M.E., Wakeman D., Longshore S.W., et al. Growth factors: possible roles for clinical management of the short bowel syndrome // Semin Pediatr Surg. 2010. Vol. 19, No. 1. P. 35–43. DOI: 10.1053/j.sempedsurg.2009.11.010

[25] Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224–1231. DOI: 10.1136/gut.2004.061440

[26] Jeppesen P.B., Sanguinetti E.L., Buchman A., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients // Gut. 2005. Vol. 54, No. 9. P. 1224–1231. DOI: 10.1136/gut.2004.061440

[27] Tappenden KA, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013;47(7):602–607. DOI: 10.1097/MCG.0b013e3182828f57

[28] Tappenden K.A., Edelman J., Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome // J Clin Gastroenterol. 2013. Vol. 47, No. 7. P. 602–607. DOI: 10.1097/MCG.0b013e3182828f57

[29] Marier J-F, Jomphe C, Peyret T, Wang Y. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome. Clin Transl Sci. 2021;14(6):2497–2509. DOI: 10.1111/cts.13117

[30] Marier J.-F., Jomphe C., Peyret T., Wang Y. Population pharmacokinetics and exposure-response analyses of teduglutide in adult and pediatric patients with short bowel syndrome // Clin Transl Sci. 2021. Vol. 14, No. 6. P. 2497–2509. DOI: 10.1111/cts.13117

[31] Martínez MI, Rumbo C, Hervás DG, et al. Experience with the use of teduglutide in paediatric patients with intestinal failure in a center in Argentina]. Acta Gastroenterológica Latinoamericana [en linea]. 2020;50(3):257–263. (In Spanish) Available: https://www.actagastro.org/numeros-anteriores/2020/Vol-50-N3/Vol50N3-PDF11.pdf

[32] Martínez M.I., Rumbo C., Hervás D.G., et al. Experiencia con el uso de teduglutide en pacientes pediátricos con fallo intestinal en un centro de Argentina // Acta Gastroenterológica Latinoamericana [en linea]. 2020. Vol. 50, No. 3. P. 257–263. Available: https://www.actagastro.org/numeros-anteriores/2020/Vol-50-N3/Vol50N3-PDF11.pdf

[33] Schwartz LK, O’Keefe SJ, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016;7(2):e142. DOI: 10.1038/ctg.2015.69

[34] Schwartz L.K., O’Keefe S.J., Fujioka K., et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome // Clin Transl Gastroenterol. 2016. Vol. 7, No. 2. P. e142. DOI: 10.1038/ctg.2015.69

[35] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71.

[36] Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews // BMJ. 2021. Vol. 372. ID n71. DOI: 10.1136/bmj.n71).

[37] Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. DOI: 10.1136/bmj.i4919

[38] Sterne J.A., Hernán M.A., Reeves B.C., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions // BMJ. 2016. Vol. 355. ID i4919. DOI: 10.1136/bmj.i4919

[39] Carter BA, Cohran VC, Cole CR, et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. J Pediatr. 2017;181:102–111.e5. DOI: 10.1016/j.jpeds.2016.10.027

[40] Carter B.A., Cohran V.C., Cole C.R., et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome // J Pediatr. 2017. Vol. 181. P. 102–111.e5. DOI: 10.1016/j.jpeds.2016.10.027

[41] ema.europa.eu [Internet]. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Revestive teduglutide Procedure No.: EMEA/H/C/002345/ 2012 [cited 2017 Jan 31]. Available at: https://www.ema.europa.eu/en/documents/assessment-report/revestive-epar-public-assessment-report_en.pdf

[42] ema.europa.eu [Электронный ресурс]. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Revestive teduglutide Procedure No.: EMEA/H/C/002345/. 2012 [дата обращения: 31.01.2017]. Доступ по: https://www.ema.europa.eu/en/documents/assessment-report/revestive-epar-public-assessment-report_en.pdf

[43] Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481.e3. DOI: 10.1053/j.gastro.2012.09.007

[44] Jeppesen P.B., Pertkiewicz M., Messing B., et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure // Gastroenterology. 2012. Vol. 143, No. 6. P. 1473–1481.e3. DOI: 10.1053/j.gastro.2012.09.007

[45] Mouillot T, Boehm V, Treton X, et al. Small-bowel adaptation: A case of morphological changes induced by teduglutide in short-bowel syndrome with intestinal failure. J Parenter Enteral Nutr. 2020;44(5):940–943. DOI: 10.1002/jpen.1805

[46] Mouillot T., Boehm V., Treton X., et al. Small-bowel adaptation: A case of morphological changes induced by teduglutide in short-bowel syndrome with intestinal failure // J Parenter Enteral Nutr. 2020. Vol. 44, No. 5. P. 940–943. DOI: 10.1002/jpen.1805

[47] Pevny S, Maasberg S, Rieger A, et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice. Clin Nutr. 2019;38(4):1745–1755. DOI: 10.1016/j.clnu.2018.07.030

[48] Pevny S., Maasberg S., Rieger A., et al. Experience with teduglutide treatment for short bowel syndrome in clinical practice // Clin Nutr. 2019. Vol. 38, No. 4. P. 1745–1755. DOI: 10.1016/j.clnu.2018.07.030

[49] Chen K, Mu F, Xie J, et al. Impact of teduglutide on quality of life among patients with short bowel syndrome and intestinal failure. J Parenter Enteral Nutr. 2020;44(1):119–128. DOI: 10.1002/jpen.1588

[50] Chen K., Mu F., Xie J., et al. Impact of teduglutide on quality of life among patients with short bowel syndrome and intestinal failure // J Parenter Enteral Nutr. 2020. Vol. 44, No. 1. P. 119–128. DOI: 10.1002/jpen.1588

[51] Chen K, Joly F, Mu F, et al. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support. Clin Nutr ESPEN. 2021;43:420–427. DOI: 10.1016/j.clnesp.2021.03.011

[52] Chen K., Joly F., Mu F., et al. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support // Clin Nutr ESPEN. 2021. Vol. 43. P. 420–427. DOI: 10.1016/j.clnesp.2021.03.011

[53] Muñiz HM, Martínez MI, Busoni VB, et al. Real-World Study of the safety and effectiveness of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. An Interim Analysis. April 2023;54:552. DOI: https://doi.org/10.1016/j.clnesp.2022.09.279

[54] Muñiz H.M., Martínez M.I., Busoni V.B., et al. Real-World Study of the safety and effectiveness of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina. An Interim Analysis. 2023. Vol. 23. P. 552. DOI: 10.1016/j.clnesp.2022.09.279

[55] Puello F, Wall E, Herlitz J, et al. Long-term outcomes with teduglutide from a single center. J Parenter Enteral Nutr. 2021;45(2):318–322. DOI: 10.1002/jpen.1838

[56] Puello F., Wall E., Herlitz J., et al. Long-term outcomes with teduglutide from a single center // J Parenter Enteral Nutr. 2021. Vol. 45, No. 2. P. 318–322. DOI: 10.1002/jpen.1838

[57] Kocoshis SA, Merritt RJ, Hill S, et al. Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: A 24-week, phase III study. J Parenter Enteral Nutr. 2020;44(4):621–631. DOI: 10.1002/jpen.1690

[58] Kocoshis S.A., Merritt R.J., Hill S., et al. Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: A 24-week, phase III study // J Parenter Enteral Nutr. 2020. Vol. 44, No. 4. P. 621–631. DOI: 10.1002/jpen.1690

[59] Ramos Boluda E, Redecillas Ferreiro S, Manrique Moral O, et al. Experience with teduglutide in pediatric short bowel syndrome: First real-life data. J Pediatr Gastroenterol Nutr. 2020;71(6):734–739. DOI: 10.1097/MPG.0000000000002899

[60] Ramos Boluda E., Redecillas Ferreiro S., Manrique Moral O., et al. Experience with teduglutide in pediatric short bowel syndrome: First real-life data // J Pediatr Gastroenterol Nutr. 2020. Vol. 71, No. 6. P. 734–739. DOI: 10.1097/MPG.0000000000002899

[61] Hill S, Carter BA, Cohran V, et al. Safety findings in pediatric patients during long-term treatment with teduglutide for short-bowel syndrome-associated intestinal failure: Pooled analysis of 4 clinical studies. J Parenter Enteral Nutr. 2021;45(7):1456–1465. DOI: 10.1002/jpen.2061

[62] Hill S., Carter B.A., Cohran V., et al. Safety findings in pediatric patients during long-term treatment with teduglutide for short-bowel syndrome-associated intestinal failure: Pooled analysis of 4 clinical studies // J Parenter Enteral Nutr. 2021. Vol. 45, No. 7. P. 1456–1465. DOI: 10.1002/jpen.2061

[63] Guz-Mark A, Hino B, Berkowitz D, et al. The variable response to teduglutide in pediatric short bowel syndrome: a single country real-life experience. J Pediatr Gastroenterol Nutr. 2022;75(3):293–298. DOI: 10.1097/MPG.0000000000003541

[64] Guz-Mark A., Hino B., Berkowitz D., et al. The variable response to teduglutide in pediatric short bowel syndrome: a single country real-life experience // J Pediatr Gastroenterol Nutr. 2022. Vol. 75, No. 3. P. 293–298. DOI: 10.1097/MPG.0000000000003541

[65] Falco EC, Lezo A, Calvo P, et al. Case report: morphologic and functional characteristics of intestinal mucosa in a child with short bowel syndrome after treatment with teduglutide: evidence in favor of GLP-2 analog safety. Front Nutr. 2022;9:866048. DOI: 10.3389/fnut.2022.866048

[66] Falco E.C., Lezo A., Calvo P., et al. Case report: morphologic and functional characteristics of intestinal mucosa in a child with short bowel syndrome after treatment with teduglutide: evidence in favor of GLP-2 analog safety // Front Nutr. 2022. Vol. 9. ID 866048. DOI: 10.3389/fnut.2022.866048

[67] Gigola F, Cianci MC, Cirocchi R, et al. Use of teduglutide in children with intestinal failure: A systematic review. Front Nutr. 2022;9:866518. DOI: 10.3389/fnut.2022.866518

[68] Gigola F., Cianci M.C., Cirocchi R., et al. Use of teduglutide in children with intestinal failure: A systematic review // Front Nutr. 2022. Vol. 9. ID 866518. DOI: 10.3389/fnut.2022.866518

[69] Diamanti A, Lezo A, D’Antiga L, et al. Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP). Dig Liver Dis. 2022;54(10):1320–1327. DOI: 10.1016/j.dld.2022.04.028

[70] Diamanti A., Lezo A., D’Antiga L., et al. Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP) // Dig Liver Dis. 2022. Vol. 54, No. 10. P. 1320–1327. DOI: 10.1016/j.dld.2022.04.028

RIGHTS & PERMISSIONS

Eco-Vector